Navigation Links
Helix BioPharma Announces Q1 2009 Financial Results
Date:12/11/2008

et loss from operations totaled $2,321,000 in the first quarter of fiscal 2009 (2008 - $1,644,000) for an increase of $677,000. Cash used in operating activities in the first quarter of fiscal 2009 totaled $1,618,000 (2008 - $1,643,000) resulting in a decrease of $25,000, despite the higher net loss from operations, and is attributable to changes in non-cash working capital, specifically higher accounts payable and accruals.

Financing activities

Financing activities in the first quarter of fiscal 2009 totaled $9,659,000 (2008 - $nil) and represents the private placement which was completed on October 2, 2008, where the Company issued 6,800,000 units at $1.68 per unit, for gross proceeds of $11,424,000.

Investing activities

Use of cash in investing activities for the in the first quarter of fiscal 2009 totaled $37,000 (2008 - $50,000) and represents capital acquisitions in both comparative quarters.

Liquidity, Capital Resources and outlook

Since inception, the Company has financed its operations from public and private sales of equity, the exercise of warrants and stock options, and, to a lesser extent, interest income from funds available for investment, government grants, investment tax credits, and revenues from distribution, licensing and contract services. Since the Company does not have net earnings from its operations, the Company's long-term liquidity depends on its ability to access the capital markets, which depends substantially on the success of the Company's ongoing research and development programs.

At October 31, 2008, the Company had cash and cash equivalents totaling $26,911,000 (July 31, 2008 - $19,057,000). The increase in cash and cash equivalents in the first quarter of fiscal 2009 is the result of a private placement completed on October 2, 2008 where the Company issued 6,800,000 units at $1.68 per unit,
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 2014 Kalorama Information says that PCR is ... the United States and is ... researcher said the FDA,s Emergency Use Authorization (EUA) to authorize ... the detection of the Ebola virus was an indication ... assess the IVD industry and its biennial survey on ...
(Date:10/27/2014)... The report “Smart Highway Market ... Communication, Monitoring), and by Display (Variable Message Signs, ... the global market into various sub-segments with in-depth ... the drivers and restraints for this market with ... 75 market tables and 37 figures spread through ...
(Date:10/26/2014)... The report "Data Center Networking ... Equipment, WAN Optimization Appliances]: Global Advancements, Worldwide Forecasts ... center networking market into various segments with an ... also identifies the factors driving this market, various ... with the future roadmaps. , Browse 106 market ...
(Date:10/25/2014)... (PRWEB) October 23, 2014 BioProcess ... winners for the 2014 BioProcess International Awards. The ... social corporate responsibility and technology applications that will ... treatments to a global patient base. , Winners ... peers during a very entertaining and exciting awards ...
Breaking Biology Technology:Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 2Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 4Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 2Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 2BioProcess International Announces Winners of the 2014 BioProcess International Awards 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 5
... BEIJING, Aug. 20 /PRNewswire-Asia-FirstCall/ -- China Medical ... leading China-based medical device,company that develops, manufactures and markets ... its unaudited financial results,for the fourth fiscal quarter ("4Q ... the first fiscal quarter ("1Q FY2009") ended June 30, ...
... , SEATTLE, Aug. 19 Cell Therapeutics, Inc. ... into an agreement to sell $30 million of shares of its Series ... in a registered offering to a single institutional investor. Each share ... holder, at any time during its existence, into approximately 628 shares of ...
... , , COLUMBIA, Md., Aug. 19 Martek Biosciences ... the results of its third quarter of fiscal 2009 on September 2, ... at 4:45 p.m. ET Martek will conduct a conference call to discuss ... call live via webcast by visiting Martek,s web site at ...
Cached Biology Technology:China Medical Technologies to Announce Unaudited Financial Results for the Fourth Fiscal Quarter and Fiscal Year ended March 31, 2009 and the First Fiscal Quarter ended June 30, 2009 on September 1, 2009 2Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants 2Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants 3
(Date:10/29/2014)... by the international Cancer Genomics of the Kidney ... between kidney cancer and exposure to aristolochic acid, ... published in Nature Communications , have important ... more than 140,000 people every year, and in ... CAGEKID, part of the International Cancer Genome Consortium ...
(Date:10/28/2014)... have published a paper in the Proceedings of ... details about key transitions in the evolution of plant ... mosses, ferns, trees and flowers growing deep in steamy ... the ornamental plants adorning our homes, all plant life ... "Our study generated DNA sequences from a vast number ...
(Date:10/28/2014)... be building a hybrid micro-grid which will integrate ... in the region, the hybrid micro-grid will test ... diesel, storage and power-to-gas technologies, and ensure these ... built under the new Renewable Energy Integration Demonstrator- ... located offshore at Semakau Landfill and is expected ...
Breaking Biology News(10 mins):Kidney cancer in Central Europe 2New study uses DNA sequences to look back in time at key events in plant evolution 2New study uses DNA sequences to look back in time at key events in plant evolution 3NTU to build region's first renewable energy integration demonstration micro-grid 2NTU to build region's first renewable energy integration demonstration micro-grid 3
... Mary Lee Dequeant, Ph.D., a Predoctoral Researcher at the ... Stowers Institute Investigator and an investigator with the Howard ... respectively, on a paper that identifies a network of ... of spine formation in the embryo. , ...
... identified the molecular signature of these epidermal neural crest ... conflicting scientific opinions by showing that these cells are ... Their work provides a valuable resource for future mouse ... the research from Dr. Maya Sieber-Blum's laboratory, co-authored by ...
... University researchers have identified a unique mechanism of action ... the treatment of multiple sclerosis. , The researchers report ... drug that was already known to affect the functioning ... white blood cells from the lymph nodes into the ...
Cached Biology News:Stem cells found in adult hair follicles may provide alternative to embryonic stem cells 2Novel mechanism of action of new drug for MS identified 2
... (100+kb), fosmid (40kb), and large plasmid insert ... othe BAC vector. On command 20-50 fold ... recombinant DNA purification. Available with blue-white screening ... for the highest insert stability. Kits include ...
... System is used in conjunction ... PCR of problematic and/or GC-rich ... Solution with 10X PCRX Amplification ... broader magnesium concentration broader annealing ...
6-carboxy-2',4,4',5',7,7'-hexachlorofluorescein, succinimidyl ester (6-HEX, SE) *single isomer*...
Mouse Exodus 2 - 12kDa...
Biology Products: